Current NCCN and Japanese Breast Cancer Society guidelines do not provide recommendations regarding optimal breast cancer treatment sequences or subsequent treatment options following CDK4/6 inhibitor therapy [2, 3]. The gene discussed is CDK4; the disease is breast cancer.